Silver Book Fact

A large set of NIH clinical trials are assessing interventions (including dietary supplements–creatine and coenzyme Q10) that may slow the progression of Parkinson’s disease.

Ravina, Bernard M., Susan C. Fagan, Robert G. Hart, Collin A. Hovinga, Diane D. Murphy, Ted M. Dawson, and John R. Marler. Neuroprotective Agents for Clinical Trials in Parkinson’s Disease: A systematic assessment. Neurology. 2003; 60(8): 1234-40. http://www.neurology.org/cgi/pmidlookup?view=long&pmid=12707423

Reference

Title
Neuroprotective Agents for Clinical Trials in Parkinson’s Disease: A systematic assessment
Publication
Neurology
Publication Date
2003
Authors
Ravina, Bernard M., Susan C. Fagan, Robert G. Hart, Collin A. Hovinga, Diane D. Murphy, Ted M. Dawson, and John R. Marler
Volume & Issue
Volume 60, Issue 8
Pages
1234-40
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • Studies by the National Center for Complementary and Alternative Medicine (NCCAM) at NIH are looking at the neuroprotective qualities of diets rich in B vitamins and antioxidant phytochemicals. These nutrients…  
  • In one study, Alzheimer’s patients who took donepezil had an increase in their prescription costs of $1,000 per patient, but saw reduced total medical costs of about 1/3–from $11,947 to…  
  • More Effective Treatment of Alzheimer’s Disease Could Save Billions: Combined Medicare and Medicaid savings from effective treatment of Alzheimer’s diease  
  • In a study of different treatments for Parkinson’s disease, results showed that the disease can be managed for up to 5 years with a reduces risk of dyskinesia.  
  • A study of Parkinson’s disease treatments found that pramipexole is a cost-effective treatment for early and advanced Parkinson’s disease. The total cost-effectiveness ratio was $8,837/QALY for patients with early Parkinson’s…